Financial Results Presentation for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 | Astellas Pharma Inc. (4503) timely disclosure

Worth reading

60In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

1100

¥100 million (increase in the full-year revenue forecast)

Wording

Conditional

How definitive the wording is.

Contents of this document

Earnings presentationSecond quarter (interim period) of the fiscal year ending March 20278 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥12,709 100 million+23.4%

Operating profit¥3,166 100 million+58.8%

Ordinary income¥3,175 100 million +63.1%interim profit before tax

Net income¥2,415 100 million +63.6%interim profit

Operating profit margin24.9

Selling, general and administrative expenses¥4,304 100 million

Full-year earnings forecast

Revenue

¥23,300 100 million

Selling, general and administrative expenses

¥8,150 100 million

R&D expenses

¥3,600 100 million

Core operating profit

¥7,000 100 million

Operating profit

¥4,600 100 million

What the company explained in this material

Self-assessment against the planThe company's self-assessment against its own plan.

Strong progress exceeding expectations

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Growth in key strategic products
Cost OptimizationApproximately ¥22 billion (cost reduction)
Foreign exchange impact on revenue¥99.3 billion
Exchange-rate impact (core operating profit)¥41.2 billion

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Exchange rate (USD) assumed in the revised fiscal 2026 forecast158 yen
Exchange rate (EUR) assumed in the revised fiscal 2026 forecast181 yen
Assumed exchange rate (USD) from the third quarter onward156 yen
Assumed exchange rate (EUR) from the third quarter onward177 yen

New initiatives

Option to obtain a worldwide exclusive development and commercialization license for DAX-044
ASP388B, ASP2020 and ASP2767 entered the clinical stage
Cost optimization through the use of AI and digital tools, the launch of global capability centers and other initiatives

Key KPIsA metric the company considers important as a management benchmark.

Revenue from key strategic products¥3,339 100 million
Year on year against the same period last year+51%
PADCEV revenue¥1,583 100 million
Year on year against the same period last year+55%
IZERVAY revenue¥562 100 million
Year on year against the same period last year+65%
VYLOY revenue¥459 100 million
Year on year against the same period last year+73%
VEOZAH revenue¥307 100 million
Year on year against the same period last year+34%

Medium-term management plan targets

TargetRecurring cost optimization of ¥200 billion

Period CoveredFY2026–FY2030

Financial targets

Gross Debt*/EBITDA1.0–1.5x

Acquisition of treasury shares

The policy is to implement purchases flexibly when surplus funds arise. The purchase limit amount, number of shares and period are Not disclosed

Contents of this document
Item	Details
Document type	Earnings presentation
Fiscal Period Covered	Second quarter (interim period) of the fiscal year ending March 2027
Net Sales	¥12,709 100 million (YoY +23.4%)
Operating profit	¥3,166 100 million (YoY +58.8%)
Ordinary income	¥3,175 100 million (interim profit before tax) (YoY +63.1%)
Net income	¥2,415 100 million (interim profit) (YoY +63.6%)
Operating profit margin	24.9
Selling, general and administrative expenses	¥4,304 100 million
Full-year earnings forecast	Revenue ¥23,300 100 million / Selling, general and administrative expenses ¥8,150 100 million / R&D expenses ¥3,600 100 million / Core operating profit ¥7,000 100 million / Operating profit ¥4,600 100 million
Self-assessment against the plan	Strong progress exceeding expectations
Breakdown of Factors Affecting the Change	Factors Growth in key strategic products / Amount Not disclosed, Factors Cost Optimization / Amount Approximately ¥22 billion (cost reduction), Factors Foreign exchange impact on revenue / Amount ¥99.3 billion, Factors Exchange-rate impact (core operating profit) / Amount ¥41.2 billion
Key KPIs	Indicator name Revenue from key strategic products / Value ¥3,339 100 million / Year on year against the same period last year +51%, Indicator name PADCEV revenue / Value ¥1,583 100 million / Year on year against the same period last year +55%, Indicator name IZERVAY revenue / Value ¥562 100 million / Year on year against the same period last year +65%, Indicator name VYLOY revenue / Value ¥459 100 million / Year on year against the same period last year +73%, Indicator name VEOZAH revenue / Value ¥307 100 million / Year on year against the same period last year +34%
Assumptions Underlying the Business Outlook	Item Exchange rate (USD) assumed in the revised fiscal 2026 forecast / Value 158 yen, Item Exchange rate (EUR) assumed in the revised fiscal 2026 forecast / Value 181 yen, Item Assumed exchange rate (USD) from the third quarter onward / Value 156 yen, Item Assumed exchange rate (EUR) from the third quarter onward / Value 177 yen
Medium-term management plan targets	Target Recurring cost optimization of ¥200 billion / Period Covered FY2026–FY2030
Financial targets	Gross Debt*/EBITDA 1.0–1.5x
Acquisition of treasury shares	The policy is to implement purchases flexibly when surplus funds arise. The purchase limit amount, number of shares and period are Not disclosed
New initiatives	Option to obtain a worldwide exclusive development and commercialization license for DAX-044, ASP388B, ASP2020 and ASP2767 entered the clinical stage, Cost optimization through the use of AI and digital tools, the launch of global capability centers and other initiatives

Items this document does not state (14)

Gross Profit MarginResults for the three months of the current quarterProgress against full-year forecastSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookAnnual DividendPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Strong growth in key strategic products, cost optimization and favorable exchange-rate movements contributed to performance. The upward revision to the full-year forecasts reflects progress that was stronger than expected.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.